Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline – Update 2012

Cutaneous melanoma (CM) is potentially the most dangerous form of skin tumour and causes 90% of skin cancer mortality. A unique collaboration of multi-disciplinary experts from the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization of...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of cancer (1990) Jg. 48; H. 15; S. 2375 - 2390
Hauptverfasser: Garbe, Claus, Peris, Ketty, Hauschild, Axel, Saiag, Philippe, Middleton, Mark, Spatz, Alan, Grob, Jean-Jacques, Malvehy, Josep, Newton-Bishop, Julia, Stratigos, Alexander, Pehamberger, Hubert, Eggermont, Alexander M.
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Kidlington Elsevier Ltd 01.10.2012
Elsevier
Schlagworte:
Adjuvant treatment
Biological and medical sciences
Combined Modality Therapy
Cutaneous melanoma
European Union
Excisional margins
Hematology, Oncology and Palliative Medicine
Humans
Interferon-α
Lymph Node Excision
Male
Medical sciences
Melanoma - diagnosis
Melanoma - therapy
Metastasectomy
Neoplasm Staging
Pharmacology. Drug treatments
Prognosis
Sentinel Lymph Node Biopsy - methods
Sentinel lymph node dissection
Skin Neoplasms - diagnosis
Skin Neoplasms - therapy
Systemic treatment
Treatment Outcome
Tumors
Tumour thickness
Metastasectomy
Interferon-α
Cutaneous melanoma
Adjuvant treatment
Systemic treatment
Sentinel lymph node dissection
Excisional margins
Tumour thickness
Skin disease
Sentinel lymph node
Alpha interferon
Malignant tumor
Consensus
Skin cancer
Thickness
Lymphadenectomy
Cancerology
Surgery
European directive
Malignant melanoma
Diagnosis
Cancer
ISSN:0959-8049, 1879-0852, 1879-0852
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Cutaneous melanoma (CM) is potentially the most dangerous form of skin tumour and causes 90% of skin cancer mortality. A unique collaboration of multi-disciplinary experts from the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization of Research and Treatment of Cancer (EORTC) was formed to make recommendations on CM diagnosis and treatment, based on systematic literature reviews and the experts’ experience. Diagnosis is made clinically and staging is based upon the AJCC system. CMs are excised with one to two centimetre safety margins. Sentinel lymph node dissection (SLND) is routinely offered as a staging procedure in patients with tumours more than 1mm in thickness, although there is as yet no clear survival benefit for this approach. Interferon-α treatment may be offered to patients with stage II and III melanoma as an adjuvant therapy, as this treatment increases at least the disease-free survival (DFS) and less clear the overall survival (OS) time. The treatment is however associated with significant toxicity. In distant metastasis, all options of surgical therapy have to be considered thoroughly. In the absence of surgical options, systemic treatment is indicated. BRAF inhibitors like vemurafenib for BRAF mutated patients as well as the CTLA-4 antibody ipilimumab offer new therapeutic opportunities apart from conventional chemotherapy. Therapeutic decisions in stage IV patients should be primarily made by an interdisciplinary oncology team (‘tumour board’).
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Instructional Material/Guideline-3
content type line 23
ISSN:0959-8049
1879-0852
1879-0852
DOI:10.1016/j.ejca.2012.06.013